Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
Journal of Biomedicine & Biotechnology|April 11, 2003
EMEA and Gene Therapy Medicinal Products Development in the European UnionMarisa Papaluca Amati, Francesco Pignatti, Alexis Nolte, et al.
The Oncologist|July 2, 2021
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple MyelomaJulio Delgado, Malgorzata Zienowicz, Paula Boudewina van Hennik, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcomaSilvia Stacchiotti, Gauthier Bouche, Ralf Herold, et al.
European Journal of Dermatology : EJD|August 14, 2014
The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP)Kyriaki Tzogani, Nithyanandan Nagercoil, Robert James Hemmings, et al.
Critical Reviews in Oncology/Hematology|May 15, 2002
Clinical trials for registration in the European Union: the EMEA 5-year experience in oncologyFrancesco Pignatti, Bo Aronsson, Spiros Vamvakas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European unionFrancesco Pignatti, Falk Ehmann, Robert Hemmings, et al.
Hemasphere|November 22, 2021
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaJulio Delgado, Irene Papadouli, Sinan B Sarac, et al.
The Oncologist|April 26, 2013
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human useElias Péan, Beatriz Flores, Ian Hudson, et al.
The Journal of Dermatological Treatment|April 5, 2013
The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: summary of the scientific assessment of the Committee for Medicinal Products for Human UseKyriaki Tzogani, Myrjam Straube, Ute Hoppe, et al.
ESMO Open|August 2, 2017
European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancerStefan Cristian Stanel, Jan Sjöberg, Tomas Salmonson, et al.
Pageof 8